An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

  title={An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients},
  author={M. Vollebergh and E. Lips and P. Nederlof and L. Wessels and M. Schmidt and E. H. van Beers and S. Cornelissen and M. Holtkamp and F. E. Froklage and E. D. de Vries and J. Schrama and J. Wesseling and M. J. van de Vijver and H. Van Tinteren and M. de Bruin and M. Hauptmann and S. Rodenhuis and S. Linn},
  journal={Annals of Oncology},
  pages={1561 - 1570}
  • M. Vollebergh, E. Lips, +15 authors S. Linn
  • Published 2011
  • Medicine
  • Annals of Oncology
  • Background: Breast cancer cells deficient for BRCA1 are hypersensitive to agents inducing DNA double-strand breaks (DSB), such as bifunctional alkylators and platinum agents. Earlier, we had developed a comparative genomic hybridisation (CGH) classifier based on BRCA1-mutated breast cancers. We hypothesised that this BRCA1-likeCGH classifier could also detect loss of function of BRCA1 due to other causes besides mutations and, consequently, might predict sensitivity to DSB-inducing agents… CONTINUE READING
    154 Citations
    EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
    • 8
    • PDF
    Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
    • 67
    • PDF
    Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy
    • 27
    • PDF
    Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • 33
    Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy
    • 17


    Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
    • 790
    • PDF
    Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
    • 122
    • PDF
    Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    • J. Palacios, E. Honrado, +11 authors J. Benítez
    • Biology, Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 2003
    • 185
    • PDF
    Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
    • 379
    • Highly Influential
    Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
    • J. Hugh, J. Hanson, +11 authors C. Vogel
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 480
    • PDF
    Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
    • 628
    • PDF
    HER2 and response to paclitaxel in node-positive breast cancer.
    • 462
    The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
    • 770
    • PDF
    Therapeutic options for triple-negative breast cancers with defective homologous recombination.
    • 40
    Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.
    • 1,084
    • PDF